Tulio L Correa

Dr. Tulio L Correa


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Pancreatology
Verified
Journal Article
Closed access
TCTulio L Correa
Tulio L Correa
MKMario Keko
Mario Keko
PDPedro Danielian
Pedro Danielian
AMAnna M. Modest
Anna M. Modest
VAVanio Antunes
Vanio Antunes
BBBruno Bockorny
Bruno Bockorny

27 January 2023 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
TCTulio L Correa
Tulio L Correa
ÁSÁurea Maria Salomão Simão
Áurea Maria Salomão Simão
JSJoyce Veceli Barros Sobreira
Joyce Veceli Barros Sobreira
FAFernanda Baeninger Anbar
Fernanda Baeninger Anbar
FYFlávia Yarshell
Flávia Yarshell
RCRicardo Tavares de Carvalho
Ricardo Tavares de Carvalho
Objectives: To evaluate the implementation of a triage protocol for palliative care (PC) during the COVID-19 pandemic (PALI-COVID) at a referral center in Brazil. Methods: A retrospective observational study was conducted. Based on the triage protocol, patients were classified into a red group, a yellow group, and a green group (GG). Patients should receive PC as recommended for each group. Results: A total of 1517 patients were included in the analysis. About 11% ( n = 162) of patients received PC. About 35% ( n = 529) of all patients died. There was a significant difference in the mortality rate between the groups; the GG had the highest mortality rate. Most patients who died (77.1%) did not receive PC. Conclusion: PALI-COVID was effective in identifying patients who had a higher risk of death and needed end-of-life support. Despite the protocol, few patients received PC.

5 December 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
RCRicardo Tavares de Carvalho
Ricardo Tavares de Carvalho
TCTulio L Correa
Tulio L Correa

16 December 2022 in Annales de Cardiologie et d'Angéiologie
Verified
Journal Article
Closed access
TCTulio L Correa
Tulio L Correa
MQMatheus Augusto Coelho Quitete
Matheus Augusto Coelho Quitete
LALuisa Tavares de Azevedo
Luisa Tavares de Azevedo
IFIsadora Assis Caiado Fraga
Isadora Assis Caiado Fraga
LTLuísa Coutinho Teixeira
Luísa Coutinho Teixeira

29 April 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MBMarcela Banegas
Marcela Banegas
DFDavid Flores-Marin
David Flores-Marin
NNNamrata Naskar
Namrata Naskar
TCTulio L Correa
Tulio L Correa
CRChloe Rotman
Chloe Rotman
ATAmelie Therrien
Amelie Therrien
INTRODUCTION: Celiac disease (CeD) is an immune-mediated enteropathy driven by gluten ingestion. Gluten challenges (GC) are commonly used to evaluate novel therapeutics and CeD mechanisms, but their associated symptom burden has not been well characterized. We aim to evaluate the proportion of subjects with gastrointestinal and extraintestinal symptoms during an experimental GC. METHODS: Pubmed, Embase, CINAHL, and Cochrane Central were searched through December 2024 for studies reporting symptoms in adult patients with CeD in remission on a gluten-free diet undergoing a GC. Studies of GC for clinical diagnosis were excluded. Eligible studies included randomized (RCT) and non-randomized trials (non-RCT) that reported symptoms. Data were pooled using random-effects meta-analysis, and heterogeneity was assessed. RESULTS: We identified 48 eligible studies with a total of 1,409 participants of which 35 were included in the meta-analysis (6 RCTs, 29 non-RCTs). The most common symptoms were abdominal pain (RCT 0.56, 95% confidence interval [CI] 0.45–0.65; non-RCT 0.40, 95% CI 0.32–0.49), bloating (RCT 0.55, 95% CI 0.38 to 0.71; non-RCT 0.37, 95% CI 0.28–0.47), and nausea (0.41, 95% CI 0.24–0.59; non-RCT 0.34, 95% CI 0.24–0.46). There was significant heterogeneity across studies, with variable GC doses and durations, no systematic reporting of all symptom categories, and missing individual data for some studies. Bloating, fatigue, flatulence, and nausea were significantly more reported in studies administering ≥6 g gluten/d. DISCUSSION: GC commonly induces gastrointestinal symptoms in patients with CeD, with abdominal pain, bloating, and nausea being most frequent. Standardized challenge protocols are needed to advance therapeutic research while minimizing symptom burden.

1 August 2023 in Journal of Medicine and Life
Verified
Journal Article
Open access
TCTulio L Correa
Tulio L Correa
CSCarolina Neiva Guedes da Silva
Carolina Neiva Guedes da Silva
FPFernanda de Sousa Pousa
Fernanda de Sousa Pousa
RCRicardo Tavares de Carvalho
Ricardo Tavares de Carvalho
This research explores the status of Palliative Care (PC) services in the state of Rio de Janeiro (RJ), Brazil, by identifying the number of services and